Review of recent clinical trials of hospital-acquired pneumonia and ventilator-associated pneumonia: a perspective from academia.
Clinical trials evaluating antimicrobial therapy for nosocomial pneumonia face many hurdles in terms of producing data that are widely applicable, supportive of safe medical practices, and able to demonstrate distinct advantages of one form of therapy over the other. Adherence to strict performance measures in conducting such trials should improve their overall quality. Such measures include enrollment of clearly defined patient populations who have a high likelihood of nosocomial pneumonia, use of diagnostic measures to confirm the presence of lower respiratory tract infection, and inclusion of broad-based pathogen distributions to ensure that the trial is applicable to the majority of patients developing nosocomial pneumonia.
Kollef
Marin H
MH
Virginia E and Sam J Golman Chair in Respiratory Intensive Care, Pulmonary and Critical Care Division, Washington University School of Medicine, and Medical Critical Care and Respiratory Care Services, Barnes-Jewish Hospital, St Louis, Missouri 63110, USA. mkollef@im.wustl.edu
D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003428:Cross Infection / Q000188:drug therapy* / Q000382:microbiology; D006761:Hospitals; D006801:Humans; D018579:Patient Selection; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D053717:Pneumonia, Ventilator-Associated / Q000188:drug therapy* / Q000382:microbiology; D012107:Research Design; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents